Pathologic complete response (pCR) is not a reliable surrogate endpoint in neoadjuvant therapy trials for early breast cancer; alternatives are needed, researchers said.
Medscape Medical News
Is pCR a Reliable Survival Surrogate in Breast Cancer Trials?
